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to 85%. This time alemtuzumab was used promptly, leading
to successful outcome (Table 1).
Conclusion: In patients with Fanconi Anemia undergoing
transplant, the development of mixed chimerismmay be due
to incomplete lympho-depletion and return of recipient
lymphocytes. In these cases, prompt and aggressive
lymphoid depleting therapy is warranted to prevent graft
rejection.262
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Background: NF-kappa B essential modulator (NEMO) is an
important activator ofNF-kappaB,which regulatesnumerous
genes involved in immune responses and ectodermal devel-
opment. Hypomorphic mutations in NEMO have been asso-
ciatedwith a spectrumof disorder such as X linked anhidrotic
ectodermal dysplasia with immunodeﬁciency (XL-EDA-ID),
X- liked immunodeﬁciencywithout ectodermal dysplasia and
isolated susceptibility to atypical mycobacteria. Currently,
allogeneic hematopoietic cell transplantation (HCT) is the
only curative therapy for patients with NEMO defects.
However, there are only fewcase reports of successful HCT for
this disorder. Herewe reportour experience of allogeneicHCT
for patients with NEMO defect.
Methods: We retrospectively analyzed the outcomes of 4
patients with NEMO defect who had undergone allogeneic
HCT between January 2005 and September 2012 in our
institution. Hypomorphic mutations in NEMO were identi-
ﬁed in all 4 patients. Three had XL-EDA-ID and one had X-
liked immunodeﬁciency without ectodermal dysplasia. Prior
to transplant all of them had recurrent bacterial infections
and two of them had disseminated atypical mycobacterial
infection. Autoimmune hemolytic anemia was noted in two
patients. The median age at transplantation was 10.5 years
(range: 3.3-18.2). All of them underwent myeloablative
preparative regimen consisting of busulfan, cyclophospha-
mide, and ATG, and busulfan kinetics were used to dose
busulfan. Two patients received matched (8/8) unrelated
donor (URD) bone marrow transplant and two received
single locus mismatch (7/8) URD bone marrow transplant. In
all patients cyclosporine and prednisone was used as GvHD
prophylaxis.
Result: Overall survival was 75% (3/4) at a median follow-up
of 59 months post-transplant (range: 12 -70). The median
time for neutrophil engraftment was 12.5 days (range: 11-
15). Grade II to III acute GVHD developed in two patients and
one patient developed chronic skin GVHD. Mixed donor
chimerism was noted in one patient needing stem cell boost
4 years after HCT. Death in one patient was due to HSV
pneumonitis and disseminated mycobacterial infection with
multi-organ failure. All surviving patients immune recon-
stituted with normal lymphocyte subpopulation, normal
distribution of CD45RA/RO, normal NK cell function and
mitogen response. Two patients are currently off immuno-
globulin replacement with good speciﬁc antibody response
to both protein and polysaccharide antigens.
Conclusion: HCT is effective in correction of innate and
adaptive immune defects associated with NEMO deﬁciency.Further follow-up and larger multi-institutional studies are
needed to better understand the role of HCT in this disorder.263
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After the ﬁrst ﬁve years workingwe evaluate the results of
Autologous Stem Cell Transplantation (ASCT) performed
between2007and2012, a total of 25ASCT,16neuroblastomas,
6HodgkinDiseases,1 LBCL,1 AML,1 PNET.Median agewas 7.2
years, 13 females, 12 males. Conditioning regimens were 17
CEM, 5 BU/MEL, 3 BEAM. Stem cell sourcewas 21 PBSC, 2 PBSC
+BM,2BM.ThemedianMNCandCD34 infusedwere5.3x108/
kg and 4.21 x 106/kg. Hematological recovery median time
was 11 days for neutrophils 12 days for platelets. Hospitali-
zation median time was 34 days, two patients (SDRA- graft
syndrome and gastrointestinal bleeding) required transfer to
the intensive care unit, both of them improved and dis-
charged. One hundred days mortality was 12% (3 patients) all
for relapseof theunderlyingdisease.Of a total of 25patients, 9
patients (36%) have died, all cases because of disease relapse.
These data show a very low transplant related mortality as
expected for ASCT, and demonstrate that autologous trans-
plantation in pediatric patients can be safely and effectively
performed indeveloping countrieswith results comparable to
those obtained in developed countries. Our goal in the future
is to assess the long termeffects on survivors and showsimilar
results in allogeneic related and unrelated transplants
currently under evaluation.264
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Introduction: Allogeneic hematopoietic stem cell trans-
plantation (HSCT) for malignant disorders is complicated by
the risk of early and late treatment related toxicities.
Reduced toxicity conditioning (RTC) regimens using
Busulfan/Fludarabine (Bu/Flu) +/- 400Gy of Total Body Irra-
diation (TBI) were designed to lower the risk of these
complications while achieving similar outcomes to the
standard myeloablative conditioning (sMAC) with Busulfan/
Cyclophosphamide (Bu/Cy) or 1200 Gy TBI/ Cyclophospha-
mide (TBI/Cy). Methods We compared outcomes of children
conditioned with sMAC versus RTC pre-HSCT between Jan
2008 and Dec 2011. In both regimens, the total dose of Buwas
adjusted to target an AUC of 16000 mM*min. Long term
outcome analysis included assessment of change in pulmo-
nary function test (PFT), cardiac function, thyroid function
and growth from baseline. Patients with GVHD of the lung
were excluded for assessing pulmonary function. Results
Sixty seven patients with AML/MDS (n¼29), ALL (n¼ 32),
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sMAC (n¼50) and RTC (n¼17). HSC source was peripheral
blood (PB) (n¼30), cord (n¼14) and bone marrow (n¼6) in
sMAC group compared to all PBSC in the RTC group. 64/67
patients engrafted with no graft failure in the RTC group. The
mean time to neutrophil engraftment was comparable in the
both groups (18.0 and 18.4 days). The time to platelet count
of>20K and>50K was signiﬁcantly shorter in the RTC group
compared to sMAC group (17 and 18days compared with 32
and 40 days respectively). OS, EFS, relapse rates, were
comparable with no signiﬁcant difference in 100 day
mortality. There was no signiﬁcant difference in the rates of
>Gr 2 aGVHD (18% sMAC and 23% RTC P ¼ .7) or cGVHD
between the two groups (36% sMAC versus 47% RTC P¼ .5). A
comparison of long term toxicity including thyroid function,
growth and cardiac function showed no signiﬁcant differ-
ence at 1 and 2yrs post HSCT. However analysis of PFT (FEV1,
FEV1/FVC ratio and VC) in 25 sMAC and 7 RTC patients
showed a signiﬁcant worsening at 2 years post HSCT in the
sMAC group versus the RTC group. (P ¼ .008, 0.04 and 0.02
respectively)
Conclusions: RTC is an effective, safe conditioning regimen
with comparable outcomes to standard regimens with
a deﬁnite improvement in platelet recovery and decreased
long term pulmonary toxicity. Larger studies are needed to
modify the RTC protocol to further minimize toxicities and
improve overall QoL of survivors.265
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Background: Hematopoietic stem cell transplantation
(HSCT) outcomes continue to improve, but there remains
signiﬁcant morbidity and mortality associated with this
therapy. Acute kidney injury (AKI) has been shown to be an
independent predictor of poor outcomes in many patient
populations. Previous studies have demonstrated that
development of AKI is associated with chronic renal disease
and mortality in patients undergoing HSCT. We sought to
determine the incidence of AKI in pediatric patients during
the ﬁrst 7 and 30 days following HSCT, and to examine the
association between the presence of AKI and 100 day and 1
year survival.
Patients and Methods:We retrospectively reviewed data on
132 consecutive pediatric patients who received HSCT at
Children's Hospital of Alabama between 2000-2007. Autol-
ogous transplants were performed in 45 (34%) patients, and
allogeneic transplants were from a matched related (19%) or
unrelated (47%) donor source. Stem cell source was bone
marrow (42%), peripheral blood (36%), or umbilical cord
blood (22%). Patients were classiﬁed as having AKI if they had
either an increase in serum creatinine (SCr) 0.3 mg/dl from
the baseline value over 7 days or  150% increase in SCr, in
accordance with contemporary AKI deﬁnitions. Baseline SCr
values for all patients were obtained during the pre-trans-
plant evaluation. The incidence of AKI was determined at 7and 30 days post-transplant. Measured outcomes were
survival at day 100 and 1 year following HSCT.
Results: During the ﬁrst 100 days following HSCT, 70 of 132
(53%) of patients met criteria for AKI. Donor source did not
appear to inﬂuence the incidence of AKI; however patients
receiving bone marrow stem cells had a higher incidence of
AKI compared to other stem cell sources. 23 of 70 patients
(33%) were diagnosed with AKI during the ﬁrst week post-
HSCT, with the remainder of patients meeting criteria within
2-4 weeks post-HSCT. Of those patients that developed AKI
by 7 days post-HSCT, three of 23 patients (13%) died before
100 days following transplant and ﬁve of 23 (22%) died prior
to 1 year post-transplant, which was not signiﬁcant when
compared to those patients without AKI. In comparison, for
patients diagnosed with AKI by day 30, 14 of 70 patients
(20%) died before 100 days following transplant, and 25 of 70
patients (35%) died prior to 1 year post-transplant. Statistical
analysis revealed that presence of AKI at 30 days post-HSCT
was associated with increased mortality at 100 days post-
transplant (P ¼ .05), but not 1-year mortality.
Conclusions: This retrospective cohort study demonstrates
that AKI is a commonmorbidity following HSCT for pediatric
patients. Furthermore, we have shown that later develop-
ment of AKI (by day 30) is associated with increased day 100
mortality. Future studies are planned to determine potential
interventions to prevent or treat AKI, which could improve
outcomes for this at-risk population.266
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Although early outcomes for sickle cell disease (SCD) after
HCT have been well-reported, comprehensive long-term
outcomes is limited. We report the ﬁrst prospective long-
term follow up of pediatric patients that have undergone an
HLA-identical sibling HCT for SCD at St. Jude. The median age
for the 14 patients (11 SS, 2 SC and 1 Sb0) was 11.03.9 yrs.
Patients received BU(500 mg/m2), CY(200 mg/kg), ATG (20
mg/kg) with CSA/MTX for GVHD prophylaxis. The median
follow-up was 9.02.3 yrs. with OS of 93%, TRM of 7% and
recurrence/graft failure of 0%. Median time to engraftment
was 165 days. Incidence for acute and chronic GVHD was
34% and 21%, respectively. Hematologic parameters signiﬁ-
cantly improved after HCT (Hgb 7.51.0 to 14.11.5g/dl; HCT
25.54.7% to 42.25.0%). Indices of hemolysis signiﬁcantly
improved after HCT (retic. 0.190.20 to 0.060.12; bili.
3.04.6 to 0.40.3 mg/dl; LDH 1103583 to 16245 u/L;
ferritin 17221068 to 122613). MRI/MRA conﬁrm previous
ﬁnding that parenchymal changes continued despite normal
erythropoiesis but stabilized 5 yrs. after HCT. Abnormal TCD
velocities normalized after HCT (16639 to 8922).
Comprehensive neuropsychiatric evaluations conﬁrm stable
cognitive function after HCT with no signiﬁcant decrease in
IQ (Full: 9418 to 87 20; performance: 10416 to 8319;
verbal 8619 to 8712). Unexpectedly, 2 patients with no/
low splenic function prior to HCT had evidence of splenic
regeneration after HCT. Moreover, hepatomegaly resolved in
all patients after HCT. Renal and cardiac function was stable
with no signiﬁcant decline in CrCl or SF. Patients did not have
